Table 2.
Effect of metabolic marker diabetes on pathologic response (no 18F-FDG-PET/CT)
| Author | Pathologic response | Diabetes (%) | No diabetes (%) | Total (%) | p-Value |
|---|---|---|---|---|---|
| Alvarado et al., 202231 a | 0.03 | ||||
| TRG1 | 5 (9.3) | 41 (21.6) | 46 (18.9) | ||
| TRG2–5 | 49 (90.7) | 149 (78.4) | 198 (81.1) | ||
| Total | 54 (100.0) | 190 (100) | 244 (100) | ||
| Boyd et al., 201041 a | 0.62 | ||||
| TRG1 | 7 (36.8) | 32 (31.1) | 39 (10.7) | ||
| TRG2–5 | 12 (63.2) | 71 (68.9) | 83 (22.7) | ||
| Total | 19 (100.0) | 103 (100.0) | 122 (33.3) |
Bold value indicates the significant values (p < 0.05)
a Univariate and multivariate regression
TRG tumor regression grade according to Mandard, 18F-FDG-PET/CT F-18 fluorodeoxyglucose positron emission tomography/computed tomography